IP Library Granted Patent US 10,702,573
Granted Patent B2
US 10,702,573 · App. 16/017,427 · Granted Jul 7, 2020

Dosing regimens for echinocandin class compounds

Inventors: Balasingam Radhakrishnan (Chapel Hill, NC); Kenneth Duke James, Jr. (Mebane, NC); Anuradha Vaidya (Raleigh, NC); Karen Polowy (Raleigh, NC)
Assignee: Cidara Therapeutics, Inc.
A61K38/08A61K9/006A61K9/0019A61K9/0053A61K9/0095A61K9/06A61K9/107A61K9/19A61K9/2018A61K38/12A61K47/10A61K47/12A61K47/14A61K47/183A61K47/186A61K47/26A61K47/36A61M5/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,702,573
App. No.
16/017,427
Granted
Jul 7, 2020
Kind
B2
Abstract

The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.

Claims (10)

1. A method of treating a subject having or susceptible to a fungal infection comprising administering to the subject an aqueous solution comprising compound 22 having the formula

or a pharmaceutically acceptable salt thereof, wherein the aqueous solution is administered to the subject intravenously at an interval of one dose every 5 to 8 days, in an amount that is sufficient to treat the fungal infection.

2. The method of claim 1 , wherein the interval is one dose every 7 days.

3. The method of claim 1 , wherein the aqueous solution is intravenously administered for at least two intervals over a period of at least two weeks.

4. The method of claim 3 , wherein the aqueous solution is intravenously administered for at least four weeks.

5. The method of claim 3 , wherein the aqueous solution is intravenously administered for at least eight weeks.

6. The method of claim 3 , wherein the aqueous solution is intravenously administered for at least twelve weeks.

7. The method of claim 1 , wherein the pharmaceutically acceptable salt of compound 22 is an acetate salt.

8. The method of claim 1 , wherein the subject is being prepared for an invasive medical procedure, is immunocompromised, or is undergoing long-term antibiotic therapy.

9. The method of claim 8 , wherein the invasive medical procedure is a transplant, a stem cell therapy, a graft, a prosthesis, an intravenous catheterization, or treatment in an intensive care unit.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2026
From: CIDARA THERAPEUTICS, INC.
To: NAPP PHARMACEUTICAL GROUP LIMITED
Reel/Frame 075286/0638 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2023
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, INC.
Reel/Frame 063665/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2023
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE, JR.; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, INC.
Reel/Frame 062541/0365 →
CHANGE OF NAME Recorded Feb 15, 2019
From: K2 THERAPEUTICS, INC.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 048356/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2019
From: SEACHAID PHARMACEUTICALS, INC.
To: K2 THERAPEUTICS, INC.
Reel/Frame 048345/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2019
From: RADHAKRISHNAN, BALASINGAM; JAMES, KENNETH DUKE, JR.; VAIDYA, ANURADHA; POLOWY, KAREN
To: SEACHAID PHARMACEUTICALS, INC.
Reel/Frame 048345/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2019
From: SEACHAID PHARMACEUTICALS, INC.
To: CIDARA THERAPEUTICS, INC.
Reel/Frame 048345/0535 →
Continuity (5)
Continuation 15371333 · Dec 7, 2016
Continuation 14386266
Provisional Application 61707142 · Sep 28, 2012
Provisional Application 61612676 · Mar 19, 2012
Related Publication 20190160141A1 · May 30, 2019
Cited By (1)
US 12,344,680